Skip to content

The Effect and Safety of the transfusion rating scheme scoring in plateau patients with elective surgery operation: a prospective, randomized, single-blind controlled clinical trial

The Effect and Safety of the transfusion rating scheme scoring in plateau patients with elective surgery operation: a prospective, randomized, single-blind controlled clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009434
Enrollment
Unknown
Registered
2016-10-15
Start date
2016-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elective surgery

Interventions

transfusion rating scheme group:Using the transfusion rating scheme to guide the perioperative blood transfusion

Sponsors

Anesthesia department of the Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (Hospital.C.T.)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Patients with preoperative Hb less than 10 g/dL, or those with intraoperative Hb may be lower than 10 g/dL (Reference formula: preoperative Hb (g/dL) - [estimated blood loss (ml)/400] <10 g/dL); (2) Patients aged not less than 14 years old; (3) Patients with the permanent elevation more than 2500 meters; (4) ASA classification: Level I~IV; (5) Patients underwent elective surgeries.

Exclusion criteria

Exclusion criteria: (1) Patients who were likely to appear excessive life-threatening hemorrhage out of control; (2) Patients with blood system diseases, such as aplastic anemia, autoimmune hemolytic anemia, hereditary spherocytosis, thalassemia, paroxysmal nocturnal hemoglobinuria, abnormal hemoglobinopathy, and hemoglobins disability of oxygen carrying (such as methemoglobinemia, etc.); (3) Patients with multiple tumors or/and tumor metastasis; (4) Patients with clear histories of preoperative coronary heart disease; (5) Patients in Neurosurgery and Obstetrics; (6) Patients must be given high hemodilution; (7) Patients had taken other drugs or been involved in other clinical trials within three months prior to the present study; (8) Patients appeared intraoperative deterioration and uncontrollable surgical bleeding.

Design outcomes

Primary

MeasureTime frame
RBC usage amount;mortality rate;complication;

Secondary

MeasureTime frame
Hospital Stay;wound healing;APACHE_IIScore changes;

Countries

China

Contacts

Public ContactZongjing Xia

Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (Hospital.C.T.)

xiazongjing163@163.com+86 13708175625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026